Today 23andMe announced the launch of its new Genotyping Services for Research (GSR) platform, providing scientists with an end-to-end service to incorporate genetic information into their studies.
23andMe, Inc., the leading personal genetics company, today announced that the National Institutes of Health (NIH) has funded a promising new study by scientists at 23andMe that could help alleviate some of the existing disparities in genetic research between people of European ancestry and people of African, Latino and Asian ancestry.
23andMe today announced a new ResearchKit module that allows researchers to seamlessly integrate genetic information into their app-based studies. ResearchKit, an open source software framework designed by Apple, makes it easy for researchers to create studies for iPhone.
23andMe, Inc., the leading personal genetics company, today announced the results of one of the largest genome-wide association studies of its kind, identifying genetic variants associated with being a morning person. Published in Nature Communications the study identified 15 locations in DNA (loci) associated with “morningness.”
23andMe, Inc., the leading personal genetics company, today announced that its service is now completely available to people both in New York and Maryland. Previously, customers in New York could not ship saliva samples from the state, while state law in Maryland prohibited direct-to-consumer genetic testing all together.
23andMe, Inc., the leading personal genetics company, today announced the launch of their new Personal Genome Service (PGS). Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe is launching an entirely new experience that includes carrier status, wellness, trait and ancestry reports.
23andMe, Inc., the leading personal genetics company, today announced it has raised $115 million in a Series E financing led by Fidelity Management & Research Company.
23andMe, Inc. today announced the appointment of Dean Schorno, CPA, as chief financial officer and head of operations for the company. In his new role, Schorno will oversee 23andMe’s global financial and clinical laboratory operations.
23andMe, Inc., the leading personal genetics company, today announced it has genotyped more than one million people worldwide. By accessing their own DNA to learn more about themselves, 23andMe customers have helped push genetic testing into the mainstream, and helped power a new genetic research model.
The three-time Emmy® award-winning, The Dr. Oz Show announced today the hiring of Michael Crupain, M.D., as Chief Of Staff of the Medical Unit. Dr. Crupain will lead the section of the show’s production responsible for researching and vetting scripts, evaluating expert guests, ordering and editing medical animations and overseeing liaisons with the show’s Medical Advisory Board. He will also lead efforts to enhance the show’s ongoing dialogue with the medical community.
23andMe, Inc., the leading personal genetics company, today announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.
Bioinformatics Pioneer Robert Gentleman, Ph.D., Joins 23andMe Leadership Team
23andMe, the leading personal genetics company, today announced the appointment of Erynn Gordon, MS, CGC as medical marketing director.
23andMe today announced the creation of a new therapeutics group and appointment of Richard Scheller, Ph.D. as chief science officer and head of therapeutics to lead it. Dr. Scheller retired in December 2014 from a distinguished 14 year career as an executive at Genentech where he was the executive vice president of research and early development.
Today marked the publication of the first ever genome-wide association study of rosacea, a common and incurable skin disorder. Led by Dr. Anne Lynn S. Chang of Stanford University’s School of Medicine, and co-authored by 23andMe, the study is the first to identify genetic factors for this condition.
23andMe, the leading personal genetics company, today announced the appointment of Kate Black as Privacy Officer and Corporate Counsel. Black brings a strong background in international, federal, and state privacy laws as well as health care regulations. As a member of the legal and regulatory team, she will be responsible for reviewing, updating and enhancing the company’s privacy and consent policies for customers in the U.S. and abroad. She joined the company January 5, 2015 and reports to Kathy Hibbs, chief legal and regulatory affairs officer.
23andMe has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.
Data by 23andMe links motion sickness to 35 genetic variants.
23andMe and Pfizer collaborate to establish new lupus research community.
23andMe and Genentech are partnering to analyze the genetic patterns associated with Parkinson's Disease.
23andMe announces the first large-scale nationwide study pinpointing differences in genetic ancestry of individuals from across the United States.
Keryx Biopharmaceuticals, Inc. today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology’s (ASN) Kidney Week meeting in Philadelphia, PA.
The Child Mind Institute presented On the Shoulders of Giants, an annual scientific symposium featuring Dr. Pasko Rakic, the recipient of the 2014 Child Mind Institute Distinguished Scientist Award. Dr. Rakic presented his outstanding work on neuronal migration and the development of the cerebral cortex in the human brain. The event highlighted his research as well as how he has influenced subsequent generations of neuroscientists.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
23andMe and Pfizer Inc. announce a new research collaboration to study Inflammatory Bowel Disease (IBD) in a nationwide initiative designed to recruit and genotype individuals who have Crohn’s disease or ulcerative colitis.
Keryx Biopharmaceuticals, Inc. announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).
The Child Mind Institute is proud to announce the open release of the Consortium for Reproducibility and Reliability (CoRR) dataset. Consisting of resting state fMRI (R-fMRI) and anatomical imaging scans repeated on 2 or more occasions in over 1500 individuals (over 5000 resting fMRI data sets in total) across 17 institutions around the world, this is an unprecedented resource from which the reliability of MRI-based imaging modalities can be determined. The initiative’s open science philosophy allows users to share the data via the 1000 Functional Connectomes Project and its International Neuroimaging Data-sharing Initiative (FCP/INDI), which were launched in 2010 by Michael P. Milham, MD, PhD, director of the Center for the Developing Brain at the Child Mind Institute, and now contains more than 10,000 brain images. This newest FCP/INDI effort is set to release later this week on June 7th.
Chicago Bears’ all-pro Brandon Marshall and his wife Michi welcomed the Child Mind Institute’s Speak Up for Kids public education tour to Chicago at the Museum of Science and Industry on May 21st for Mind the Gap: Integrating Physical and Mental Healthcare
The Child Mind Institute held its fourth annual Advocacy Award Dinner to raise critical funds to continue providing life-changing mental health care for children, pursuing scientific breakthroughs, and expanding public education and outreach efforts.
The Child Mind Institute awarded Dr. Nora Volkow the 2013 Child Mind Institute Distinguished Scientist Award for her work in brain science and addiction. The Institute also honored Dr. Volkow's protégés Dr. Gene-Jack Wang, Dr. Michael Michaelides and ten exceptional high school seniors from the New York City metropolitan area.
Under-served teenagers use digital journalism to inspire self-esteem and community activism.
A recent AIG study shows that hospital C-Suite and Risk Managers struggle with maintaining patient safety. Maximizing patient safety is the top priority for hospital C-Suite executives and Risk Managers in the United States – but, “lack of teamwork, negative culture and poor communication” will present barriers to patient safety in the future – according to a new survey commissioned by American International Group (AIG) in consultation with patient safety expert, Dr. Marty Makary, MD, MPH.
This May, the Child Mind Institute presents Speak Up for Kids, a month-long online dialogue to promote children's mental health and eliminate barriers to care. Responding to President Obama's call for a national conversation about mental health in the wake of the tragedy in Newtown, Speak Up for Kids brings together the nation's mental health leadership and over 75 partner organizations to give parents the information they need to help remove stigma and get kids effective mental health care. The heart of Speak Up for Kids is a series of online events that tackle the big issues facing families today.
With our hearts and minds are still with those in Newtown, Connecticut, and the tragic loss of children and teachers, most schools will be resuming on Monday across the country. This is a good thing, because it is essential that children fall back into ordinary routines after hearing disturbing and frightening news. Children find comfort in the familiar, and going back to school and any after-school activities helps build healthy, resilient children.
National findings suggest better understanding and support may empower people to seek help early for fibromyalgia symptoms.
CUMC’s program in narrative medicine, with $1 million Josiah Macy Jr. Foundation Grant, to enroll students from nursing, dental, medical and public health schools in collaborative program
Four clinical sites in the U.S. have completed required training and are certified to provide novel therapy to patients using the NovoTTF-100A System™; three additional clinical sites planned by year end.
As cold and flu season is upon us, text4baby -a free text messaging program for pregnant and new moms -shared information today from the service’s first-ever interactive educational module, showing how the service can quickly and efficiently gather important data on how moms make choices about taking steps to prevent the flu.
People who are informed and proactive about their health tend to distance themselves from those with unhealthy habits, potentially missing opportunities to spread good health.
Expanded center doubles scale of physical, occupational and speech therapy services.
Bob Costas Returns as Emcee for New York Fundraiser on Monday, September 26 to Benefit The Buoniconti Fund to Cure Paralysis
The Johnson & Johnson Campaign for Nursing's Future sponsors national contest, honoring nurses' dedication to the profession.
Peer-reviewed study involving more than 3 million pharmacy patients shows calendar blister packaging improves adherence to self-administered medications for long-term use.
Local and national partners unite to improve maternal and infant health one text at a time.
Join the Johnson & Johnson Campaign for Nursing’s Future during National Nurses Week and take this opportunity to thank a nurse.
National survey finds parents and coaches need more youth sports safety information.
National findings reveal greater awareness, earlier diagnosis, and support help reduce daily life challenges
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting.
Commitment from Johnson & Johnson Enables Growth of Nation’s Largest Mobile Health Initiative.
Data from the first phase III clinical trial of NovoCure’s NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, noninvasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right